Evidence map›Paper›PMID 40344452›Full record

ArticleThoracic cancer2025

Association of Baseline Serum Uric Acid With Venous Thromboembolism and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer.

Xue-Li Zhang, Chen Zhang, Lu Lang, Jia-Wen Yi, Min Zhu, Yu-Hui Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xue-Li ZhangDepartment of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0001-6796-0776
Chen ZhangDepartment of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Lu LangDepartment of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Jia-Wen YiDepartment of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Min ZhuDepartment of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Yu-Hui ZhangDepartment of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0002-4373-1845

Funding

Clinical Research Incubation Project, Beijing Chao-Yang Hospital, Capital Medical University CYFH202212National Natural Science Foundation of China 82370058Reform and Development Program of Being Institute of Respiratory Medicine Ggyfz202513
6 · The paper itself

Abstract

objectiveThis study aimed to analyze the association between baseline serum uric acid (SUA) level and venous thromboembolism (VTE) and clinical outcomes in patients with non-small cell lung cancer (NSCLC). MATERIALS AND

methodsWe conducted a prospective analysis of 626 patients with newly diagnosed or recurrent/progressive NSCLC between September 2021 and August 2024. Receiver operating characteristic (ROC) curve was used to determine the optimal cutoff values for risk factors related to VTE, and clinical characteristics and treatment outcomes were collected and compared according to these values. Fine-Gray regression analyses were used to identify the risk factors of VTE, and survival was analyzed using log-rank test and Cox regression analysis.

resultsIn the study, 72 patients (11.50%) experienced VTE. Patients with VTE had a higher baseline SUA level than those without VTE (p = 0.000). The optimal threshold of baseline SUA to predict VTE was 310 μmol/L. The incidence of VTE was higher in the high SUA group than that of the low SUA group (19.1% vs. 7.9%, p < 0.001). In multivariable analysis, the baseline SUA level was associated with the risk of VTE (sub-distribution hazard ratio (SHR) = 2.830, 95% CI 1.689-4.742, p = 0.000). Additionally, the higher SUA level was associated with a worse disease-free survival (DFS) in newly diagnosed patients with NSCLC staged I-IIIA (adjusted HR = 1.948, 95% CI 1.121-3.384, p = 0.018).

conclusionsAmong NSCLC patients, a baseline feature of high SUA (≥ 310 μmol/L) was associated with an increased risk of VTE and a worse clinical outcome.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsUric AcidVenous ThromboembolismAgedFemaleHumansMaleMiddle AgedPrognosisProspective StudiesRisk FactorsUric Acidnon‐small cell lung cancerprognosisserum uric acidvenous thromboembolism

Identifiers

PMID40344452
PMCPMC12062515

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.